Aliases & Classifications for Agoraphobia

MalaCards integrated aliases for Agoraphobia:

Name: Agoraphobia 12 73 54 44 15 17 70 32
Fear of Open Spaces 12


External Ids:

Disease Ontology 12 DOID:593
MeSH 44 D000379
NCIt 50 C34362
SNOMED-CT 67 154885006
ICD10 32 F40.0
UMLS 70 C0001818

Summaries for Agoraphobia

Disease Ontology : 12 A phobic disorder involving the specific anxiety about being in a place or situation where escape is difficult or embarrassing or where help may be unavailable.

MalaCards based summary : Agoraphobia, also known as fear of open spaces, is related to hypochondriasis and personality disorder. An important gene associated with Agoraphobia is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Peptide ligand-binding receptors and Calcium signaling pathway. The drugs Paroxetine and Clonazepam have been mentioned in the context of this disorder. Affiliated tissues include cortex, pituitary and amygdala, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Agoraphobia is an anxiety disorder characterized by symptoms of anxiety in situations where the person... more...

Related Diseases for Agoraphobia

Diseases related to Agoraphobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 148)
# Related Disease Score Top Affiliating Genes
1 hypochondriasis 30.6 SLC6A4 HTR2A HTR1A
2 personality disorder 30.5 SLC6A4 MAOA HTR2A HTR1A COMT
3 animal phobia 30.4 SLC6A4 PTK7
4 acute stress disorder 30.3 SLC6A4 HTR1A
5 separation anxiety disorder 30.3 SLC6A4 MAOA HTR1A CTU2 COMT
6 depression 30.2 SLC6A4 NOS1 MAOA HTR2A HTR1A
7 phobic disorder 30.2 TMEM132D SLC6A4 PTK7 MAOA HTR2A HTR1A
8 eating disorder 30.1 SLC6A4 HTR2A HCRTR1 COMT
9 alcohol use disorder 30.0 SLC6A4 HTR2A HTR1A COMT
10 obsessive-compulsive personality disorder 30.0 SLC6A4 HTR2A COMT
11 mental depression 30.0 SLC6A4 SLC6A2 MAOA HTR2A HTR1A COMT
12 generalized anxiety disorder 30.0 SLC6A4 SLC6A2 NPSR1 MAOA HTR2A HTR1A
13 obsessive-compulsive disorder 30.0 SLC6A4 PTK7 NPSR1 MAOA HTR2A HTR1A
14 endogenous depression 29.9 SLC6A4 MAOA HTR2A HTR1A COMT
15 social phobia 29.9 SLC6A4 PTK7 MAOA LOC110806262 HTR2A HTR1A
16 neurotic disorder 29.9 SLC6A4 MAOA HTR2A HTR1A COMT
17 melancholia 29.8 SLC6A4 MAOA LOC110806262 HTR2A HTR1A
18 irritable bowel syndrome 29.8 SLC6A4 HTR2A HTR1A COMT
19 constipation 29.7 SLC6A4 SLC6A2 NOS1 GRP
20 atypical depressive disorder 29.7 SLC6A4 MAOA HTR2A HTR1A
21 bulimia nervosa 29.7 SLC6A4 MAOA HTR2A COMT
22 cyclothymic disorder 29.7 SLC6A4 HTR2A COMT
23 mood disorder 29.7 SLC6A4 SLC6A2 MAOA HTR2A HTR1A COMT
24 post-traumatic stress disorder 29.7 SLC6A4 MAOA HTR2A COMT
25 panic disorder 29.7 TMEM132D SLC6A4 SLC6A2 PTK7 NPSR1 MIR22
26 phobia, specific 29.6 TMEM132D SLC6A4 MAOA HTR2A HTR1A CTU2
27 tic disorder 29.5 SLC6A4 MAOA HTR2A COMT
28 tobacco addiction 29.4 SLC6A4 MAOA HTR2A COMT
29 alcohol dependence 29.4 SLC6A4 SLC6A2 MAOA HTR2A HTR1A COMT
30 dysthymic disorder 29.4 SLC6A4 SLC6A2 MAOA HTR2A HTR1A CTU2
31 sleep disorder 29.4 SLC6A4 HTR2A HTR1A HCRTR1 COMT
32 borderline personality disorder 29.4 SLC6A4 MAOA HTR2A HTR1A COMT
33 major depressive disorder 29.3 TMEM132D SLC6A4 SLC6A2 MAOA HTR2A HTR1A
34 bipolar disorder 29.2 SLC6A4 SLC6A2 NOS1 MAOA HTR2A HTR1A
35 anxiety 29.1 TMEM132D SLC6A4 SLC6A2 PTK7 NPSR1 MAOA
36 schizophrenia 28.9 SLC6A4 SLC6A2 NOS1 MAOA HTR2A HTR1A
37 attention deficit-hyperactivity disorder 28.7 SLC6A4 SLC6A2 NPSR1 NOS1 MAOA HTR2A
38 disease of mental health 27.4 TMEM132D SLC6A4 SLC6A2 PTK7 NPSR1 NOS1
39 panic disorder 1 11.2
40 avoidant personality disorder 10.4
41 inhibited male orgasm 10.4 SLC6A4 HTR1A
42 corneal dystrophy, lisch epithelial 10.3 MAOA HTR1A
43 retrograde amnesia 10.3 SLC6A4 HTR1A
44 paraphilia disorder 10.3 SLC6A4 MAOA
45 amphetamine abuse 10.3 SLC6A4 SLC6A2
46 severe combined immunodeficiency 10.3
47 drug psychosis 10.2 HTR1A COMT
48 somatization disorder 10.2 SLC6A4 HTR1A COMT
49 drug-induced mental disorder 10.2 HTR1A COMT
50 flying phobia 10.2 MAOA COMT

Graphical network of the top 20 diseases related to Agoraphobia:

Diseases related to Agoraphobia

Symptoms & Phenotypes for Agoraphobia

GenomeRNAi Phenotypes related to Agoraphobia according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.32 SLC6A4
2 Decreased viability GR00381-A-1 9.32 GRP HTR1A SLC6A4
3 Decreased viability GR00381-A-3 9.32 GRP HTR1A SLC6A4
4 Decreased viability GR00386-A-1 9.32 GRP
5 Decreased viability GR00402-S-2 9.32 GRP HTR1A

MGI Mouse Phenotypes related to Agoraphobia:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 CCKBR COMT GLRB GRP GRPR HCRTR1
2 cardiovascular system MP:0005385 9.7 CCKBR COMT GLRB GRP HTR1A MAOA
3 nervous system MP:0003631 9.4 CCKBR COMT GLRB GRP HCRTR1 HTR1A

Drugs & Therapeutics for Agoraphobia

Drugs for Agoraphobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 28)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Citalopram Approved Phase 4 59729-33-8 2771
Sertraline Approved Phase 4 79617-96-2 68617
Dexetimide Withdrawn Phase 4 21888-98-2
8 GABA Modulators Phase 4
9 Cytochrome P-450 Enzyme Inhibitors Phase 4
10 Central Nervous System Stimulants Phase 4
11 Dopamine Agents Phase 4
12 Dopamine Uptake Inhibitors Phase 4
13 Psychotropic Drugs Phase 4
14 Serotonin Uptake Inhibitors Phase 4
15 Neurotransmitter Agents Phase 4
16 Antidepressive Agents Phase 4
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
Lecithin Experimental Phase 3 8002-43-5
19 Anticonvulsants Phase 3
20 Sunflower Phase 3
Cycloserine Approved Phase 2 68-41-7 401 6234
22 Antimetabolites Phase 2
23 Anti-Bacterial Agents Phase 2
24 Antibiotics, Antitubercular Phase 2
25 Antitubercular Agents Phase 2
26 Anti-Infective Agents Phase 2
Magnesium Sulfate Approved, Investigational, Vet_approved 7487-88-9 24083
28 Pharmaceutical Solutions

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Long-term, Open, Naturalistic, Randomized Clinical Trial With Clonazepam and Paroxetine in Panic Disorder With or Without Agoraphobia Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
2 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
3 Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety Recruiting NCT03522844 Phase 4 Escitalopram
4 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
5 Mechanisms of CBT-Treatment Effects in Patients With Panic Disorder and Panic Disorder With Agoraphobia: The Role of Interoceptive Exposure Unknown status NCT01323556 Phase 2, Phase 3
6 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3 Paroxetine or other medication - algorithm used
7 Dynamic Treatment vs. CBT for Panic Disorder Completed NCT00353470 Phase 3
8 Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Not yet recruiting NCT03549819 Phase 3 Cannabidiol (CBD) Oil Capsules;Sunflower Lecithin Oil in Capsule
9 Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Withdrawn NCT04569760 Phase 3 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose);Placebo Oil
10 Exposure Therapy for Fear of Falling in Older Adults Completed NCT01609322 Phase 2
11 Augmentation of Exposure Therapy With D-Cycloserine in Patients With Agoraphobia With or Without Panic Disorder Completed NCT01928823 Phase 2 D-Cycloserine
12 Intensive Treatment of Adolescent Panic and Agoraphobia Completed NCT00576719 Phase 2
13 The Modular Protocol for Mental Health (MPMH): A Pilot Randomised Clinical Trial of a Transdiagnostic Psychological Treatment for Mood and Anxiety Disorders in Adults Completed NCT03143634 Phase 1, Phase 2
14 Effects of Cannabidiol (CBD) on Reconsolidation Disruption of Pathological Interoceptive Aversive Memory in Humans. Recruiting NCT04726475 Phase 1, Phase 2
15 A Comparative Controlled Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia Unknown status NCT00129610
16 Improving Access to the Treatment of Anxiety and Depression Among Linguistic Minorities: A Feasibility Open Trial of Internet-Delivered Transdiagnostic Cognitive Behaviour Therapy Amongst French Canadians Young Adults Unknown status NCT03156556
17 Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction Completed NCT00004366
18 Virtual Reality Exposure Therapy in Agoraphobic Participants Completed NCT00734370
19 Thought Field Therapy and Cognitive Therapy for Agoraphobia - a Randomized Controlled Intervention Study Where the Efficacy of Thought Field Therapy is to be Compared to Cognitive Therapy Completed NCT00932919
20 Efficacy of Hypnotherapy Compared to a Wait-list Control Group in the Treatment of Agoraphobia Completed NCT03684577
21 Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Panic Disroder and Agoraphobia Completed NCT01446172
22 Moderators and Mediators of Treatment Change in Panic Disorder and Agoraphobia Completed NCT03547180
23 Phase 2/3 Study of Panic Control Treatment vs Panic-Focussed Psychodynamic Psychotherapy Under Randomized and Self-Selection Conditions Completed NCT01606592
24 Effect of Cognitive-behavior Therapy on Panic Symptomatology and the Activation of the Brain's Fear Network to Panic-related Body Symptoms in Patients With Panic Disorder Completed NCT04568109
25 Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder, a Prospective, Randomized Pilot Study With Wait List as Control Group. Completed NCT00202709
26 Internet-based Exposure Therapy for Panic Disorder: A Randomized Controlled Pilot Study Completed NCT03061448
27 Virtual Reality for Panic Disorder With Agoraphobia: a Clinical Trial Completed NCT03101332
28 Effectiveness of Specific Model of Cognitive-Behavioral Therapy in Panic Disorder Patients With Agoraphobia Completed NCT00772746
29 The Influence of Physical Activity (Prior to In-vivo Exposure) on the Effect of Cognitive Behavioural Therapy in Patients With Panic Disorder and Agoraphobia Completed NCT01928810
30 Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia Completed NCT00004367
31 The Influence of Physical Activity on the Effect of Cognitive Behavioural Therapy, Neurobiological Parameters and Information Processing in Patients With Panic Disorder With/Without Agoraphobia Completed NCT01788800
32 Evaluation of Occupational Balance, Fear and Agoraphobia in Adults Completed NCT04681261
33 Trans-diagnostic Group CBT vs. Standard Group CBT for Depression, Social Anxiety and Agoraphobia/Panic Disorder: A Pragmatic, Multicenter Non-inferiority Randomized Controlled Trial Completed NCT02954731
34 Cognitive-behavioural Therapyin Panic Disorder: the Preparation of Patients With Panic Disorder for Interoceptive and in Vivo Agoraphobic Exposure Completed NCT01025908
35 A Pragmatic Randomized Controlled Trial of Group Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders in Primary Care Completed NCT02811458
36 Providing Tools for Effective Care and Treatment of Anxiety Disorders (AD): Outcomes, Mediators and Moderators of Enhanced Extinction Completed NCT02605668
37 Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in Norway. A Randomized Controlled Study Completed NCT02150265
38 Predicting Treatment Response to Exposure Therapy Using a CO2 Habituation Paradigm in Patients With High Levels of Anxiety Sensitivity Completed NCT03925987
39 Examining the Effects of Reduced Environmental Stimulation on Anxiety Completed NCT03051074
40 Exposure Initializes Therapy - Treatment Of Homebound Patients Extended Recruiting NCT04460378
41 Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia Recruiting NCT01680237
42 The Effect of a Transdiagnostic, Self-guided Internet Intervention ("Velibra") for Waitlist Patients With Anxiety Disorders Recruiting NCT04793828
43 Construction of a Questionnaire on Panic Disorder and Agoraphobia Recruiting NCT03885453
44 Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety Recruiting NCT02810171
45 A Comparison of the Efficacy of Transdiagnostic Behavior Therapy and Disorder-specific Therapy in Veterans With PTSD, Anxiety, and Depression Recruiting NCT04293341
46 Comparison of Patient-Centered Versus Provider-Centered Delivery of Cognitive Behavioral Treatment (CBT) for Pediatric Anxiety and Obsessive Compulsive Disorder (OCD) Recruiting NCT03528109
47 Building an Outcomes Assessment Infrastructure to Assess Youth in the McLean Anxiety Mastery Program at McLean Hospital Recruiting NCT02305537
48 Effect of Mindfulness Meditation on Physiological Response to Unpredictable Stimuli Active, not recruiting NCT03206437
49 Project Collabri Flex - The Effect of a Danish Model for Collaborative Care for People With Anxiety and Depression in General Practice Active, not recruiting NCT03113175
50 Investigating Floatation-REST as a Novel Technique for Reducing Anxiety and Depression Enrolling by invitation NCT03899090

Search NIH Clinical Center for Agoraphobia

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cochrane evidence based reviews: agoraphobia

Genetic Tests for Agoraphobia

Anatomical Context for Agoraphobia

MalaCards organs/tissues related to Agoraphobia:

Cortex, Pituitary, Amygdala, Temporal Lobe, Brain, Eye, Heart

Publications for Agoraphobia

Articles related to Agoraphobia:

(show top 50) (show all 3110)
# Title Authors PMID Year
Associations between serotonin-related gene polymorphisms and panic disorder. 61 54
15670397 2005
Norepinephrine transporter (NET) promoter and 5'-UTR polymorphisms: association analysis in panic disorder. 54 61
15722184 2005
Association of a functional 1019C>G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. 61 54
14984628 2004
Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. 61 54
10870873 2000
Influence of personality on behavioral response to cholecystokinin-tetrapeptide in patients with panic disorder. 54 61
8771610 1996
A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. 61 54
7786960 1995
Evaluation of mechanism of change in transdiagnostic cognitive behaviour therapy using single case experimental design. 61
33388441 2021
Disorder-specific internet-based cognitive-behavioral therapy in treating panic disorder, comorbid symptoms and improving quality of life: A meta-analytic evaluation of randomized controlled trials. 61
33643852 2021
Internet-delivered exposure therapy versus internet-delivered cognitive behavioral therapy for panic disorder: A pilot randomized controlled trial. 61
33774558 2021
Stress Hormones as Predictors of Response to Cognitive Behavior Therapy in Panic Disorder. 61
33735885 2021
Decreased defensive reactivity to interoceptive threat after successful exposure-based psychotherapy in patients with panic disorder. 61
33731674 2021
Psychiatric Co-Morbidities in Post-Traumatic Stress Disorder: Detailed Findings from the Adult Psychiatric Morbidity Survey in the English Population. 61
32705407 2021
The association between anxiety disorders and hippocampal volume in older adults. 61
33661669 2021
The impact of generalized anxiety disorder in obsessive-compulsive disorder patients. 61
33812219 2021
Quality of life in children with tuberous sclerosis complex: A pediatric cohort study. 61
33225634 2021
Relationship between anxiety symptoms, clinical control and quality of life of children with asthma: A cross-sectional study. 61
33789000 2021
Cohort profile of the longitudinal Netherlands Study of Depression and Anxiety (NESDA) on etiology, course and consequences of depressive and anxiety disorders. 61
33773360 2021
Social anxiety and agoraphobia symptoms effectively treated by Prompt Mental Health Care versus TAU at 6- and 12-month follow-up: Secondary analysis from a randomized controlled trial. 61
33393688 2021
Affective Temperaments, Panic Disorder and Their Bipolar Connections. 61
33808711 2021
Evaluating a Hybrid Web-Based Training Program for Panic Disorder and Agoraphobia: Randomized Controlled Trial. 61
33661121 2021
"Don´t tell me that I am hysterical": Unmet needs of patients with panic disorder. 61
33754599 2021
Development of a cognitive bias modification intervention for anxiety disorders in primary care. 61
33629751 2021
Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. 61
32900266 2021
Separation Anxiety Disorder in Panic Disorder Patients with and without Comorbid Agoraphobia. 61
33577430 2021
The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: an ACTTION systematic review. 61
33383293 2021
EMDR Treatment of Panic Disorder with Agoraphobia: Case Report. 61
33638960 2021
Association between Uncinate Fasciculus Integrity and Agoraphobia Symptoms in Female Patients with Panic Disorder. 61
33508789 2021
The Effect of Patient's Choice of Cognitive Behavioural or Psychodynamic Therapy on Outcomes for Panic Disorder: A Doubly Randomised Controlled Preference Trial. 61
33227785 2021
Predicting marriage and divorce in obsessive-compulsive disorder. 61
32783604 2021
DetectaWeb-Distress Scale: A Global and Multidimensional Web-Based Screener for Emotional Disorder Symptoms in Children and Adolescents. 61
33658965 2021
Catastrophic cognitions about coronavirus: the Oxford psychological investigation of coronavirus questionnaire [TOPIC-Q]. 61
33478604 2021
Validation and Construct Validity of the Posttraumatic Avoidance Behaviour Questionnaire in a Sample of Trauma-Exposed Black Women. 61
33440052 2021
Younger, more senior, and most vulnerable? Interaction effects of age and job seniority on psychological distress and quality of life among firefighters. 61
32853012 2021
Prevalence of Common mental disorders in older adults: Results from the National Mental Health Survey of India. 61
33212298 2021
Are Comorbid Disorders Associated with Changes in Gambling Activity? A Longitudinal Study of Younger and Older Subjects with DSM-IV Pathological Gambling. 61
33475936 2021
Effectiveness of guided internet-based interventions in the indicated prevention of depression in green professions (PROD-A): Results of a pragmatic randomized controlled trial. 61
33096333 2021
African Americans' and Black Caribbeans' Religious Coping for Psychiatric Disorders. 61
33378231 2021
A Pilot Study of the Efficacy of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Treating Posttraumatic Psychopathology: A Randomized Controlled Trial. 61
33453140 2021
Which psychotherapy is effective in panic disorder? And which delivery formats are supported by the evidence? Study protocol for two systematic reviews and network meta-analyses. 61
33372071 2020
Large-group one-session treatment: Feasibility and efficacy in 138 individuals with phobic fear of flying. 61
33038799 2020
A topography of 21 phobic fears: network analysis in an epidemiological sample of adult twins. 61
33298223 2020
Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study. 61
33046351 2020
Group transdiagnostic cognitive-behavior therapy for anxiety disorders: a pragmatic randomized clinical trial. 61
33261700 2020
Association of Serotonin Transporter Gene (5-HTTLPR/rs25531) Polymorphism with Comorbidities of Panic Disorder. 61
33333511 2020
Fundamental frequency during cognitive preparation and its impact on therapy outcome for panic disorder with Agoraphobia. 61
32987282 2020
Preferences for panic control treatment and panic focused psychodynamic psychotherapy for panic disorder - who chooses which and why? 61
33148129 2020
Anxiety disorders and healthcare utilization: A systematic review. 61
32818687 2020
A longitudinal study of personality traits, anxiety, and depressive disorders in young adults. 61
33190525 2020
Increased rates of eating disorders and their symptoms in women with major depressive disorder and anxiety disorders. 61
32844425 2020
Influence of Comorbid Psychiatric Disorders on the Risk of Development of Alcohol Dependence by Genetic Variations of ALDH2 and ADH1B. 61
32890420 2020

Variations for Agoraphobia

Expression for Agoraphobia

Search GEO for disease gene expression data for Agoraphobia.

Pathways for Agoraphobia

Pathways related to Agoraphobia according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
11.73 SLC6A4 SLC6A2 COMT
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12 10.6 MAOA COMT
Show member pathways

GO Terms for Agoraphobia

Cellular components related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.2 TMEM132D STMN1 SLC6A4 SLC6A2 PTK7 NPSR1
2 plasma membrane GO:0005886 10.03 SLC6A4 SLC6A2 PTK7 NPSR1 NOS1 HTR2A
3 integral component of membrane GO:0016021 9.97 TMEM132D SLC6A4 SLC6A2 PTK7 NPSR1 MAOA
4 synapse GO:0045202 9.43 SLC6A4 NOS1 HTR2A HTR1A HCRTR1 GLRB
5 integral component of plasma membrane GO:0005887 9.28 SLC6A4 SLC6A2 PTK7 NPSR1 HTR2A HTR1A

Biological processes related to Agoraphobia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.02 NPSR1 HTR2A HTR1A HCRTR1 GRPR GRP
2 response to drug GO:0042493 9.88 SLC6A4 SLC6A2 HTR2A COMT
3 chemical synaptic transmission GO:0007268 9.65 SLC6A2 HTR2A HTR1A HCRTR1 GLRB
4 signal transduction GO:0007165 9.65 STMN1 PTK7 NPSR1 HTR2A HTR1A HCRTR1
5 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.61 HTR2A GRPR CCKBR
6 response to pain GO:0048265 9.59 SLC6A2 COMT
7 vasoconstriction GO:0042310 9.58 SLC6A4 HTR1A
8 behavior GO:0007610 9.57 HTR2A HTR1A
9 neurotransmitter biosynthetic process GO:0042136 9.56 SLC6A4 NOS1
10 catecholamine metabolic process GO:0006584 9.55 MAOA COMT
11 neurotransmitter catabolic process GO:0042135 9.54 MAOA COMT
12 social behavior GO:0035176 9.54 SLC6A4 GRPR GRP
13 negative regulation of potassium ion transport GO:0043267 9.52 NOS1 HTR2A
14 dopamine catabolic process GO:0042420 9.51 MAOA COMT
15 monoamine transport GO:0015844 9.49 SLC6A4 SLC6A2
16 neurotransmitter reuptake GO:0098810 9.46 SLC6A4 SLC6A2
17 serotonin receptor signaling pathway GO:0007210 9.4 HTR2A HTR1A
18 psychomotor behavior GO:0036343 9.32 GRPR GRP
19 response to external biotic stimulus GO:0043207 9.16 GRPR GRP
20 neuropeptide signaling pathway GO:0007218 9.02 NPSR1 HCRTR1 GRPR GRP GLRB

Molecular functions related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.63 NPSR1 HTR2A HTR1A HCRTR1 GRPR CCKBR
2 neurotransmitter receptor activity GO:0030594 9.43 HTR2A HTR1A GLRB
3 neurotransmitter transporter activity GO:0005326 9.37 SLC6A4 SLC6A2
4 neuropeptide receptor activity GO:0008188 9.32 NPSR1 GRPR
5 monoamine transmembrane transporter activity GO:0008504 8.96 SLC6A4 SLC6A2
6 serotonin binding GO:0051378 8.8 SLC6A4 HTR2A HTR1A

Sources for Agoraphobia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....